Eurosurv. Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025

[tetano]

• François Blanquart[SUP]1[/SUP] , Vincent Vieillefond[SUP]2[/SUP] , Benoit Visseaux[SUP]3[/SUP] , Claire Nour Abou Chakra[SUP]4[/SUP] , Marta C Nunes[SUP]4,5[/SUP] , Alexandra Jacques[SUP]6[/SUP] , Stephanie Haim-Boukobza[SUP]7[/SUP] , Laurence Josset[SUP]8,9[/SUP] , Valentin Wehrle[SUP]10[/SUP] , Guillaume Deleglise[SUP]11[/SUP] , Thomas Duret[SUP]11[/SUP] , Marie Anne Rameix-Welti[SUP]12,13[/SUP] , Bruno Lina[SUP]8,9[/SUP] , Vincent Enouf[SUP]13[/SUP] , on behalf of the RELAB study group[SUP]14[/SUP] , Antonin Bal[SUP]8,9[/SUP]

​Influenza circulates at high levels in Europe since November 2024. Using a test-negative study based on data from French community laboratories between October 2024 and February 2025, we estimated vaccine effectiveness (VE) against PCR-detected influenza infection (44,420/15,052; positive/negative individuals). For all age groups, the overall VE was 42% (95% CI: 37–46%), with 26% (95% CI: 18–34%) against influenza A and 75% (95% CI: 66–82%) against influenza B. Among individuals ≥ 65-year-olds VE was 22% (95% CI: 13–30%) and among 0–64-year-olds, 60% (95% CI: 56–65%).

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2025.30.7.2500074